Ingevity Corporation (NYSE:NGVT) Receives Consensus Rating of “Hold” from Analysts

Ingevity Corporation (NYSE:NGVT) has been given an average recommendation of “Hold” by the five ratings firms that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and two have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $80.00.

NGVT has been the topic of a number of recent analyst reports. Wells Fargo & Company boosted their price objective on Ingevity from $65.00 to $75.00 and gave the company an “equal weight” rating in a research note on Friday, February 27th. Zacks Research raised Ingevity to a “hold” rating in a research note on Tuesday, December 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Ingevity in a report on Thursday, January 22nd. BMO Capital Markets restated an “outperform” rating and set a $83.00 price target on shares of Ingevity in a report on Monday, March 2nd. Finally, Wall Street Zen cut Ingevity from a “strong-buy” rating to a “buy” rating in a report on Monday, March 9th.

Ingevity Trading Down 0.9%

NGVT opened at $70.74 on Monday. Ingevity has a twelve month low of $28.49 and a twelve month high of $77.46. The company has a fifty day moving average of $69.35 and a 200-day moving average of $60.58. The stock has a market cap of $2.50 billion, a PE ratio of -15.21 and a beta of 1.31. The company has a quick ratio of 0.79, a current ratio of 1.33 and a debt-to-equity ratio of 39.10.

Ingevity (NYSE:NGVT) last released its earnings results on Wednesday, February 25th. The company reported $0.58 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.74 by ($0.16). Ingevity had a negative net margin of 13.51% and a positive return on equity of 126.25%. The firm had revenue of $255.10 million during the quarter, compared to analyst estimates of $257.27 million. During the same quarter in the previous year, the firm earned $0.95 EPS. Ingevity’s quarterly revenue was down 3.2% on a year-over-year basis. Ingevity has set its FY 2026 guidance at 4.800-5.20 EPS. On average, sell-side analysts predict that Ingevity will post 4.45 EPS for the current year.

Institutional Investors Weigh In On Ingevity

Large investors have recently bought and sold shares of the stock. Global Retirement Partners LLC acquired a new position in shares of Ingevity during the fourth quarter valued at about $27,000. Oakworth Capital Inc. acquired a new stake in shares of Ingevity in the 3rd quarter valued at about $28,000. Meeder Asset Management Inc. acquired a new stake in shares of Ingevity in the 4th quarter valued at about $33,000. Geneos Wealth Management Inc. increased its position in Ingevity by 85.8% in the 2nd quarter. Geneos Wealth Management Inc. now owns 838 shares of the company’s stock valued at $36,000 after buying an additional 387 shares in the last quarter. Finally, Headlands Technologies LLC bought a new stake in Ingevity in the 2nd quarter valued at about $46,000. 91.59% of the stock is currently owned by institutional investors and hedge funds.

About Ingevity

Ingevity Corporation, traded as NGVT, is a specialty chemicals and performance materials company headquartered in North Charleston, South Carolina. The company operates two primary business units: Performance Chemicals and Performance Materials. The Performance Chemicals segment produces and markets specialty chemicals derived largely from wood and other natural feedstocks, including rosin acids, tall oil fatty acids and esters, as well as specialty petroleum resins. These products serve a broad range of industries, including paper, adhesives, coatings, oilfield drilling and consumer goods.

The Performance Materials segment develops and manufactures activated carbon products and composites for applications such as automotive emissions control, industrial air and water purification, and spill containment.